103
Participants
Start Date
February 7, 2023
Primary Completion Date
September 29, 2025
Study Completion Date
October 19, 2025
KPI-012
KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
KPI-012 Vehicle
KPI-012 formulation with no active drug
Principal Investigator, New York
Principal Investigator, Rockville Centre
Principal Investigator, Pittsburgh
Principal Investigator, Philadelphia
Principal Investigator, Norfolk
Principal Investigator, Morgantown
Principal Investigator, Garner
Principal investigator, Durham
Principal Investigator, Atlanta
Principal Investigator, Orange City
Principal Investigator, Miami
Principal Investigator, Miami
Principal Investigator, Dothan
Principal Investigator, Nashville
Principal Investigator, Memphis
Principal Investigator, Louisville
Principal Investigator, Powell
Principal Investigator, Indianapolis
Principal Investigator, Carmel
Principal Investigator, Kenosha
Principal Investigator, Rapid City
Principal Investigator, Chesterfield
Principal Investigator, St Louis
Principal Investigator, Kansas City
Principal Investigator, Kansas City
Principal Investigator, Houston
Principal Investigator, San Antonio
Principal Investigator, Austin
Principal Investigator, Austin
Principal Investigator, Aurora
Principal Investigator, Littleton
Principal Investigator, Fort Collins
Principal Investigator, Los Angeles
Principal Investigator, Los Angeles
Principal Investigator, Pasadena
Principal Investigator, La Jolla
Principal Investigator, Loma Linda
Principal Investigator, Irvine
Principal Investigator, Rancho Cordova
Principal Investigator, Seattle
Principal Investigator, Boston
Principal Investigator, Boston
Principal Investigator, Palisades Park
Principal Investigator, Caba
Principal Investigator, Rosario
Principal Investigator, San Juan
Lead Sponsor
Collaborators (1)
Kala Pharmaceuticals, Inc.
INDUSTRY
Combangio, Inc
INDUSTRY